Global EGFR Mutation Test Market Size By Type (DNA Sequencing, Kits), By Application (Cancer Hospitals, Clinical Research Institutes), By Region, And Segment Forecasts, 2023 to 2032

lobal EGFR Mutation Test Market Report Description

The Global EGFR Mutation Test Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 2.3 billion by 2031, growing at a CAGR of 9.4% during the forecast period. The market is driven by the increasing prevalence of non-small cell lung cancer (NSCLC), growing demand for personalized medicine, and advancements in molecular diagnostics technologies.

EGFR (Epidermal Growth Factor Receptor) mutation testing plays a critical role in guiding targeted therapy decisions for lung cancer patients. With the rise in oncology-focused research, the market is expanding rapidly across diagnostic laboratories, hospitals, and research centers. Furthermore, early detection initiatives, rising healthcare spending, and expanding insurance coverage for genetic testing are fueling demand worldwide.

Market Drivers

Rising Incidence of Lung Cancer Globally

NSCLC accounts for over 80% of lung cancer cases, with EGFR mutations present in a significant subset of patients, particularly in Asian populations. The growing cancer burden is driving the adoption of EGFR mutation testing as a standard diagnostic tool.

Shift Toward Precision Medicine

Targeted therapies such as tyrosine kinase inhibitors (TKIs) are highly effective in EGFR-positive patients. The push for personalized oncology treatments is increasing the demand for rapid and accurate mutation testing.

Advancements in Molecular Diagnostics

Next-generation sequencing (NGS)-based assays, liquid biopsy solutions, and highly sensitive PCR-based tests are improving detection accuracy and turnaround time, supporting market growth.

Market Restraints

High Cost of Molecular Testing

Advanced EGFR mutation tests, especially NGS panels, can be expensive and are not always fully reimbursed, limiting adoption in low- and middle-income countries.

Limited Awareness and Infrastructure in Developing Regions

Lack of trained personnel, diagnostic facilities, and standardized testing protocols can slow down the market expansion in emerging economies.

Market Opportunities

Growth of Liquid Biopsy Solutions

Non-invasive EGFR mutation detection through circulating tumor DNA (ctDNA) is gaining traction, opening new revenue streams for test developers.

Expansion in Emerging Markets

Rapid improvements in healthcare infrastructure and government initiatives for cancer screening in Asia-Pacific and Latin America present lucrative opportunities.

Collaborations Between Pharma and Diagnostics Companies

Increasing partnerships between pharmaceutical companies and molecular diagnostic players to co-develop companion diagnostics will accelerate market penetration.

Market by System Type Insights

PCR-based EGFR Mutation Tests accounted for the largest market share in 2023 due to their cost-effectiveness, high sensitivity, and widespread availability in clinical settings.

NGS-based EGFR Mutation Testing is expected to register the fastest CAGR, driven by the growing adoption of comprehensive genomic profiling for broader mutation detection.

Market by End-use Insights

Hospitals and Oncology Clinics dominated the market, accounting for over 50% of total revenue in 2023, as they are primary centers for cancer diagnosis and treatment.

Reference Laboratories & Diagnostic Centers are expected to experience significant growth due to the outsourcing trend of genetic testing services.

Market by Regional Insights

Asia-Pacific held the largest market share in 2023, driven by the high prevalence of EGFR mutations in lung cancer patients in China, Japan, and South Korea.

North America follows closely, supported by advanced healthcare infrastructure, favorable reimbursement policies, and high adoption of targeted therapies.

Europe continues to expand steadily with government initiatives promoting early cancer detection.

Latin America & Middle East are emerging markets with improving diagnostic accessibility.

Competitive Scenario

Key players in the Global EGFR Mutation Test Market include:

Roche Diagnostics

Qiagen N.V.

Thermo Fisher Scientific Inc.

Illumina, Inc.

Bio-Rad Laboratories, Inc.

Agilent Technologies

Guardant Health

Biocartis NV

These companies are focusing on product innovation, companion diagnostic approvals, strategic partnerships, and geographic expansion.

Recent Developments:

2024: Roche launched an upgraded cobas EGFR Mutation Test v3 optimized for liquid biopsy applications.

2024: Qiagen expanded its QIAstat-Dx platform to include a multi-gene panel for lung cancer mutation profiling.

2023: Guardant Health received FDA approval for Guardant360 CDx, a liquid biopsy companion diagnostic for EGFR-targeted therapies.

Scope of Work – Global EGFR Mutation Test Market

Key Market Developments

2024: Roche Diagnostics introduced an advanced liquid biopsy EGFR assay approved for monitoring therapy resistance in NSCLC.

2023: Thermo Fisher Scientific partnered with a major pharma company to develop a companion diagnostic for next-gen EGFR inhibitors.

2023: Qiagen launched a rapid EGFR mutation detection kit for resource-limited settings.

FAQs

1. What is the current market size of the Global EGFR Mutation Test Market?

The market size was USD 1.1 billion in 2023.

2. What is the major growth driver of the Global EGFR Mutation Test Market?

The market is primarily driven by the increasing incidence of lung cancer and rising demand for precision oncology solutions.

3. Which region is the largest during the forecast period in the Global EGFR Mutation Test Market?

Asia-Pacific is the largest and fastest-growing region due to the high EGFR mutation prevalence in lung cancer patients.

4. Which segment accounted for the largest market share in the Global EGFR Mutation Test Market?

PCR-based EGFR Mutation Tests held the largest share in 2023, while NGS-based tests are growing rapidly.

5. Who are the key market players in the Global EGFR Mutation Test Market?

Key players include Roche Diagnostics, Qiagen, Thermo Fisher Scientific, Guardant Health, Illumina, and Bio-Rad Laboratories.

Would you like me to create a polished PDF version of this report description for professional use? Or should I also add an infographic/visual summary?